Page
%P
-
Chapter and Conference Paper
No advantage for the use of an early high-dose chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors
The results of the treatment of non-seminomatous germ cell tumors (NSGCT) have been dramatically improved by Cisplatin-based chemotherapy regimens and selective indication of surgery. Approximately 80 % of all...
-
Chapter and Conference Paper
High-dose chemotherapy with hematologic rescue for high-risk non-seminomatous germ cell tumors
Despite progress in the treatment of disseminated non-seminomatous germ cell tumors (NSGCT), 20–30%of patients do not achieve CR or relapse [1]. We evaluated high-dose chemotherapy (HDC) followed by autologous...